Early Phase 3 trials like JAVELIN adding immunotherapy to chemoradiation failed to improve outcomes. However, subgroup analyses consistently showed a potential benefit in PD-L1 high-expressing patients, a crucial lesson that informed the design of subsequent, more successful studies.

The CheckMate 9LA regimen provides exceptional benefit to PD-L1 negative and squamous histology NSCLC patients. This is significant because these subgroups often respond poorly to other immunotherapy combinations, with Dr. Carbone noting some trials where the control arm outperformed pembrolizumab in these patients.

The focus on KRAS is expanding beyond small molecule inhibitors to diverse immunotherapies. Approaches like TCR T-cells, mRNA vaccines targeting KRAS neoepitopes, and novel amphiphil vaccines are being developed to activate a patient's immune system against their specific cancer mutations.

The HARMONY-2 study showed Ivanesimab delivered a median progression-free survival of 11.3 months compared to 5.8 months for Pembrolizumab in PD-L1 positive NSCLC. Analysis confirmed Pembrolizumab performed as expected, suggesting the dual VEGF/PD-1 blockade provides a genuinely superior clinical benefit over PD-1 inhibition alone.

The KRAS G12D mutation, unlike the more common G12C, often occurs in younger, never-smoking lung cancer patients who previously lacked targeted therapy options. The high response rate (61%) and good tolerability of the G12D inhibitor Zoldanrasib could fill a significant unmet need in this specific demographic.

Contrary to the standard 'TKI-first' approach for driver mutations, a study in MET exon 14 skipping NSCLC suggests a different strategy. Patients with high PD-L1 expression appeared to have better outcomes with first-line chemoimmunotherapy, reserving the targeted therapy for later. This challenges the conventional wisdom of prioritizing the driver mutation over immunotherapy biomarkers in this specific subgroup.

Despite major advances in immunotherapy, patient selection remains crude compared to targeted therapies. PD-L1 is still the primary, yet imperfect, biomarker used. Dr. Carbone highlights an urgent need to develop better predictive biomarkers to customize immunotherapy regimens, as is standard for targeted agents.

The success of perioperative osimertinib means oncologists cannot choose the optimal strategy (targeted therapy vs. chemoimmunotherapy) for resectable lung cancer without first knowing the patient's EGFR, ALK, and PD-L1 status. This elevates biomarker profiling from a metastatic-setting tool to a critical first step in early-stage disease.

For patients with actionable mutations like EGFR or ALK, targeted therapy is the priority, regardless of PD-L1 score. Starting immunotherapy first in these patients can significantly increase the risk of developing severe pneumonitis (ILD) when they later switch to targeted therapy like osimertinib.